Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SFRP1
REST API REST API
Homo sapiens
SFRP1 is differentially expressed in 318 experiments: 177 organism parts: lung, liver, ... (175 more);, 217 disease states: normal, glioblastoma, ... (215 more);, 99 cell types 455 cell lines 37 compound treatments and 73 other conditions.
Synonyms FRP-1, SARP2, FRP
Orthologs Sfrp1 (Mus musculus)   sfrp1b (Danio rerio)   SFRP1 (Gallus gallus)   Q4H2U5_CIOIN (Ciona intestinalis)   SFRP1 (Bos taurus)   sfrp1a (Danio rerio)   Sfrp1 (Rattus norvegicus)   sfrp1 (Xenopus laevis)   SFRP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, negative regulation of cell growth, embryo development, frizzled binding, negative regulation of transcription, DNA-dependent, protein binding, digestive tract morphogenesis, negative regulation of peptidyl-tyrosine phosphorylation, intracellular, negative regulation of cell proliferation, extracellular space, Wnt receptor signaling pathway, planar cell polarity pathway, positive regulation of cell proliferation, heparin binding, proteinaceous extracellular matrix, negative regulation of apoptosis, male gonad development, extracellular region, somitogenesis, female gonad development, positive regulation of apoptosis, negative regulation of Wnt receptor signaling pathway, gonad development, identical protein binding, hemopoiesis, negative regulation of JUN kinase activity, cysteine-type endopeptidase activity, Wnt-protein binding, negative regulation of cell migration, negative regulation of BMP signaling pathway, positive regulation of smoothened signaling pathway, somatic stem cell maintenance, canonical Wnt receptor signaling pathway, response to drug, positive regulation of cell growth, DNA fragmentation involved in apoptotic nuclear change, cell surface, PDZ domain binding, negative regulation of epithelial cell proliferation, extracellular matrix, positive regulation of Wnt receptor signaling pathway, negative regulation of gene expression, brain development, positive regulation of transcription, DNA-dependent, dorsal/ventral axis specification, negative regulation of androgen receptor signaling pathway, development of primary male sexual characteristics, negative regulation of ossification, menstrual cycle phase, regulation of angiogenesis, positive regulation of focal adhesion assembly, negative regulation of fibroblast proliferation, cellular response to growth factor stimulus, cellular response to estradiol stimulus, neural tube closure, negative regulation of osteoblast proliferation, cellular response to hypoxia, negative regulation of osteoblast differentiation, negative regulation of osteoclast differentiation, negative regulation of epithelial to mesenchymal transition, drug binding, bone trabecula formation, negative regulation of B cell differentiation, positive regulation of canonical Wnt receptor signaling pathway, hemopoietic progenitor cell differentiation, regulation of ossification, osteoblast differentiation, negative regulation of insulin secretion, cellular response to estrogen stimulus, cellular response to transforming growth factor beta stimulus, positive regulation of epithelial cell proliferation, cellular response to heparin, positive regulation of stress fiber assembly, cellular response to vitamin D, cellular response to tumor necrosis factor, positive regulation of cell-matrix adhesion, vasculature development, neural crest cell fate commitment, regulation of branching involved in prostate gland morphogenesis, regulation of establishment of planar polarity, neural tube development, convergent extension involved in somitogenesis, hemopoietic stem cell differentiation, positive regulation of Rac GTPase activity, cellular response to X-ray, prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis, negative regulation of canonical Wnt receptor signaling pathway, ureteric bud development, positive regulation of fat cell differentiation, cellular response to interleukin-1, cellular response to starvation, Wnt receptor signaling pathway involved in somitogenesis, regulation of cell cycle process, cellular response to prostaglandin E stimulus, negative regulation of canonical Wnt receptor signaling pathway involved in controlling type B pancreatic cell proliferation, stromal-epithelial cell signaling involved in prostate gland development, cellular response to BMP stimulus, negative regulation of planar cell polarity pathway involved in axis elongation, positive regulation of non-canonical Wnt receptor signaling pathway, negative regulation of bone remodeling, planar cell polarity pathway involved in neural tube closure, response to organic cyclic compound, cellular response to fibroblast growth factor stimulus, positive regulation of fibroblast apoptosis, negative regulation of cysteine-type endopeptidase activity, negative regulation of fibroblast apoptosis, negative regulation of Wnt receptor signaling pathway involved in dorsal/ventral axis specification, Wnt-activated receptor activity, anterior/posterior pattern specification
InterPro Term Netrin_domain, Netrin_module_non-TIMP, Frizzled_dom
UniProt Accession Q6ZSL4, A8KAM5, Q8N474, Q9BZZ6
Search EB-eye ENSG00000104332
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1937
2
E-MTAB-37, E-MTAB-62
HCC2157
2
E-MTAB-37, E-MTAB-62
LNCaP
2
E-GEOD-14464, E-GEOD-14990
MCF-10A
2
E-TABM-420, E-GEOD-14990
MDA-MB-231
2
E-TABM-420, E-MTAB-62
449 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-19397, E-GEOD-21668, E-GEOD-3920, ... (48 experiments)

Factor Value U/D Experiments
plasma cell
2
E-MEXP-2360, E-GEOD-6691
2
2
E-TABM-145, E-TABM-130
testis - germ cell
2
E-AFMX-5, E-TABM-145
embryonic stem cell
1
2
E-GEOD-2248, E-MEXP-930, E-GEOD-26672
fibroblast
1
2
E-MEXP-466, E-GEOD-3920, E-GEOD-3204
erythropoietic
1
E-GEOD-9894
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, ... (72 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-37, E-MTAB-62, E-MTAB-57, E-GEOD-3726
glioblastoma
1
4
E-MTAB-62, E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-GEOD-6014 ... (5 experiments)
cervical carcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-1331
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
211 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-5542, E-TABM-782, E-GEOD-3720, ... (27 experiments)

Factor Value U/D Experiments
Infergen + interferon-gamma
1
E-GEOD-5542
FLAP
1
E-GEOD-3202
control - interferon-gamma
1
E-GEOD-7216
IL-13 (Homo sapiens)
1
E-GEOD-3183
phoshate buffered saline
1
E-GEOD-3720
Cxcl12
1
1
E-GEOD-7307
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, E-GEOD-19348, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-19018, E-GEOD-20033, E-GEOD-6236, ... (8 experiments)

Dfs follow up
studied in E-GEOD-22541

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-2152, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-5681, E-GEOD-12773, E-TABM-127, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-20559, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-GEOD-1926, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-3407, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-19330

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Processing time: 0.498 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM